| |
| |
| | Catalent Gains Access to Commercial Spray Drying Manufacturing Capabilities in UK | |
|
|
| |
| | | | On July 9, 2019, Catalent signed an agreement with Sanofi Active Ingredient Solutions to gain access to commercial spray drying manufacturing capabilities at its Haverhill, United Kingdom facility. This strengthens Catalent’s position as the world leading provider for oral dose development and manufacturing. Earlier this year, Catalent announced the addition of commercial spray drying capabilities at its Winchester, Kentucky facility. Combined with the Haverhill facility, Catalent’s customers now have access to: |
|
|---|
| | |
|
| | End-to-end accelerated spray drying solutions from early development through clinical supply and scale-up manufacturing of commercial dose formState-of-the-art facilities in the United States and EuropeEarly-phase spray drying development sites in San Diego, CA and Nottingham, UK Explore Catalent’s Spray Drying capabilities for your next project. |
|
| |
|
| |
| |
| | Catalent Gene Therapy Partners with Several Innovators and Acquires Capabilities to Accelerate Growth | |
|
|
| |
| | Catalent Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy |
|
| |
|
| |
| | On July 16, Catalent announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA). Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space at the new, state-of-the-art commercial manufacturing center near Baltimore-Washington International (BWI) Airport established by Paragon Gene Therapy, a unit of Catalent Biologics. |
|
| |
|
| |
| |
| |
| |
| | Novavax and Catalent Biologics Enter into a Strategic Partnership, Allowing Paragon Gene Therapy to Expand Footprint with Acquisition of Manufacturing Assets and Capabilities |
|
| |
|
| |
| | Novavax will be entering into a long-term arrangement with Paragon under which Paragon will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art manufacturing equipment, people and space to accelerate the growth of its gene therapy development and manufacturing business. |
|
| |
|
| |
| |
| |
| |
| | Amicus Therapeutics Announces a Strategic Agreement with Catalent Biologics for Gene Therapy Development and Manufacturing |
|
| |
|
| |
| | The agreement supports clinical and commercial supply needs for Pompe and other preclinical lysosomal disease gene therapy programs. |
|
| |
|
| |
| |
| |
| |
| | Catalent’s Partner, Passage Bio, Announces New Dedicated Gene Therapy Manufacturing Suite |
|
| |
|
| |
| | The dedicated suite, located at Paragon Gene Therapy’s cGMP manufacturing facility near Baltimore-Washington International Airport in Harmans, MD, will support Passage Bio’s clinical through commercial milestones for AAV-delivered therapeutics |
|
| |
|
| |
| |
| |
| |
| | | | Join us August 12 – 16, 2019 at the Bioprocessing Summit in Boston, Massachusetts. Visit our booth 134 and discuss your most complex biologic challenges with our team of experts. Attend the Women in Bio panel discussion including Kathleen Munster, VP, Quality, Catalent, to learn strategies for successful career advancement.
|
|
|---|
| | |
|
| |
| |
| |
| | Setting Up Your Drug for Clinical Success: Strategies and Considerations from Discovery to Clinic |
|
| |
|
| |
| | Attend this Discovery to Clinic event September 10 in Malmo, Sweden. This event will focus on key considerations for transitioning a molecule from discovery through clinical studies including molecule developability assessment, phase-appropriate formulation selection, integration of product development and clinical supply, and creating an appropriate clinical study design. |
|
| |
|
| |
| |
| |
| | A Catalyst in Drug Development | |
|
|
| |
| | William Wei Lim Chin
Technical Specialist
|
|
| |
|
| | | William Wei Lim Chin is a Technical Specialist with Catalent Pharma Solutions. He has experience with in vitro and in vivo evaluation of pharmaceutical formulations and drug delivery systems. As a technical specialist, he applies problem-solving acumen and recommends solutions while ensuring technical specifications are met. Learn how William uses formulation science and DMPK modeling to determine a molecule’s developability to help guide a molecule into preclinical studies. Discover this catalyst in drug development, and access William’s additional research on oral delivery, pediatric drug formulation and more.
|
|
|---|
| | |
|
| |
| |
| |
| |
| |
| | | | BIOLOGICS Webinar: “Development Strategies for Difficult to Express Proteins” - In this webinar, industry experts outline two successful case studies taking complex biopharmaceuticals to clinical production. Watch the webinar to learn about new technologies that can improve the robustness of cell line and development timelines Ebook: “Achieving A Successful Drug Product Technology Transfer” - Technology transfer is a challenging and multi-faceted endeavor, with multiple variables that must be carefully considered. Gain insights for a successful process transfer for manufacturing a drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Poster: “Biophysical Characterization of a Therapeutic MAb And Its Associated Antigen-binding Fragments” - Stress modifications are an important quality attribute in biologic development. In this white paper, Catalent experts developed a fast, comprehensive characterization method applied during stability studies to promote a broader, deeper understanding of stress modifications on therapeutic proteins. Download now to learn more. |
|
|---|
| | |
|
| |
| |
| |
| |
| |
| |
| |
| | We are growing. We are hiring. Join us! | |
|
|
| | | | Your talents, ideas and passion are essential to our mission: to develop, manufacture and supply products that help people live better healthier lives. Join one of our rapidly growing teams in Bloomington, Madison, Kansas City, Eberbach, or Swindon. To hear what our employees have to say about working at Catalent, click here. |
|
|---|
| | |
|
| |
| | Upcoming Expert Presentations, Webinars and Events | |
|
|
| |
| The BioProcessing Summit | August 12 – 16, 2019 | Boston, Massachusetts | USA BPI Conference East | September 9 - 12, 2019 | Boston, Massachusetts | USA Discovery to Clinic | September 10, 2019 | Malmö, Sweden NLS Days 2019 | September 10 – 12, 2019 | Malmö, Sweden Pharma Forum | September 18 - 19, 2019 | Swabisch Hall, Germany
EBDC 2019 | September 25 – 26, 2019 | Heidelberg, Germany |
|
| |
|
| |
| | | Every brand has a challenge. We have a solution. |
| | | | | | | | or call +1 877 891 9609 to speak with one of our experts today! |
| | |
|
| | To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.
Catalent Pharma Solutions respects your privacy.
Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement or the website, its owner(s) or the content. | | © 2019, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
